-
公开(公告)号：US20090093419A1
公开(公告)日：2009-04-09
申请号：US12169882
申请日：2008-07-09
申请人： Hideki Fujikura , Nobuhiko Fushimi , Toshihiro Nishimura , Takeshi Nakabayashi , Masayuki Isaji
发明人： Hideki Fujikura , Nobuhiko Fushimi , Toshihiro Nishimura , Takeshi Nakabayashi , Masayuki Isaji
IPC分类号： A61K31/7056
CPC分类号： A61K45/06 , A61K31/7056 , C07H17/02 , A61K2300/00
摘要： The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R represents a hydrogen atom, a lower alkyl group or a group forming a prodrug; one of Q and T represents a group represented by the general formula: (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom; and with the proviso that P does not represent a hydrogen atom when R represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, which exert an inhibitory activity in human SGLT2 and have an improved oral absorption, and therefore are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutically acceptable salts thereof, and pharmaceutical uses thereof.
摘要翻译： 本发明提供由以下通式表示的吡喃葡萄糖氧吡唑衍生物：其中R表示氢原子，低级烷基或形成前药的基团; Q和T之一表示由通式表示的基团：（其中P表示氢原子或形成前药的基团），而另一个表示低级烷基或卤代（低级烷基）基团; R2表示氢原子，低级烷基，低级烷氧基，低级烷硫基，卤代（低级烷基）或卤素原子; 并且条件是当R表示氢原子或低级烷基时，P不表示氢原子，或其药学上可接受的盐，其在人SGLT2中具有抑制活性并具有改善的口服吸收，因此可用作 用于预防或治疗与高血糖相关的疾病如糖尿病，糖尿病并发症或肥胖症的药剂及其药学上可接受的盐及其药学用途。
-
公开(公告)号：US07989424B2
公开(公告)日：2011-08-02
申请号：US12169882
申请日：2008-07-09
申请人： Hideki Fujikura , Nobuhiko Fushimi , Toshihiro Nishimura , Takeshi Nakabayashi , Masayuki Isaji
发明人： Hideki Fujikura , Nobuhiko Fushimi , Toshihiro Nishimura , Takeshi Nakabayashi , Masayuki Isaji
CPC分类号： A61K45/06 , A61K31/7056 , C07H17/02 , A61K2300/00
摘要： The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R represents a hydrogen atom, a lower alkyl group or a group forming a prodrug; one of Q and T represents a group represented by the general formula: (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom; and with the proviso that P does not represent a hydrogen atom when R represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, which exert an inhibitory activity in human SGLT2 and have an improved oral absorption, and therefore are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutically acceptable salts thereof, and pharmaceutical uses thereof.
摘要翻译： 本发明提供由以下通式表示的吡喃葡萄糖氧吡唑衍生物：其中R表示氢原子，低级烷基或形成前药的基团; Q和T之一表示由通式表示的基团：（其中P表示氢原子或形成前药的基团），而另一个表示低级烷基或卤代（低级烷基）基团; R2表示氢原子，低级烷基，低级烷氧基，低级烷硫基，卤代（低级烷基）或卤素原子; 并且条件是当R表示氢原子或低级烷基时，P不表示氢原子，或其药学上可接受的盐，其在人SGLT2中具有抑制活性并具有改善的口服吸收，因此可用作 用于预防或治疗与高血糖相关的疾病如糖尿病，糖尿病并发症或肥胖症的药剂及其药学上可接受的盐及其药学用途。
-
公开(公告)号：US07393838B2
公开(公告)日：2008-07-01
申请号：US11247356
申请日：2005-10-12
申请人： Hideki Fujikura , Nobuhiko Fushimi , Toshihiro Nishimura , Takeshi Nakabayashi , Masayuki Isaji
发明人： Hideki Fujikura , Nobuhiko Fushimi , Toshihiro Nishimura , Takeshi Nakabayashi , Masayuki Isaji
CPC分类号： A61K45/06 , A61K31/7056 , C07H17/02 , A61K2300/00
摘要： The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R represents a hydrogen atom, a lower alkyl group or a group forming a prodrug; one of Q and T represents a group represented by the general formula: (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom; and with the proviso that P does not represent a hydrogen atom when R represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, which exert an inhibitory activity in human SGLT2 and have an improved oral absorption, and therefore are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutically acceptable salts thereof, and pharmaceutical uses thereof.
-
公开(公告)号：US20060035847A1
公开(公告)日：2006-02-16
申请号：US11247356
申请日：2005-10-12
申请人： Hideki Fujikura , Nobuhiko Fushimi , Toshihiro Nishimura , Takeshi Nakabayashi , Masayuki Isaji
发明人： Hideki Fujikura , Nobuhiko Fushimi , Toshihiro Nishimura , Takeshi Nakabayashi , Masayuki Isaji
IPC分类号： A61K31/7056 , C07H17/02
CPC分类号： A61K45/06 , A61K31/7056 , C07H17/02 , A61K2300/00
摘要： The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R represents a hydrogen atom, a lower alkyl group or a group forming a prodrug; one of Q and T represents a group represented by the general formula: (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo (lower alkyl) group or a halogen atom; and with the proviso that P does not represent a hydrogen atom when R represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, which exert an inhibitory activity in human SGLT2 and have an improved oral absorption, and therefore are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutically acceptable salts thereof, and pharmaceutical uses thereof.
摘要翻译： 本发明提供由以下通式表示的吡喃葡萄糖氧吡唑衍生物：其中R表示氢原子，低级烷基或形成前药的基团; Q和T之一表示由通式表示的基团：（其中P表示氢原子或形成前药的基团），而另一个表示低级烷基或卤代（低级烷基）基团; R 2表示氢原子，低级烷基，低级烷氧基，低级烷硫基，卤代（低级烷基）或卤素原子; 并且条件是当R表示氢原子或低级烷基时，P不表示氢原子，或其药学上可接受的盐，其在人SGLT2中具有抑制活性并具有改善的口服吸收，因此可用作 用于预防或治疗与高血糖相关的疾病如糖尿病，糖尿病并发症或肥胖症的药剂及其药学上可接受的盐及其药学用途。
-
公开(公告)号：US07465713B2
公开(公告)日：2008-12-16
申请号：US11247216
申请日：2005-10-12
申请人： Hideki Fujikura , Nobuhiko Fushimi , Toshihiro Nishimura , Takeshi Nakabayashi , Masayuki Isaji
发明人： Hideki Fujikura , Nobuhiko Fushimi , Toshihiro Nishimura , Takeshi Nakabayashi , Masayuki Isaji
CPC分类号： A61K45/06 , A61K31/7056 , C07H17/02 , A61K2300/00
摘要： The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R represents a hydrogen atom, a lower alkyl group or a group forming a prodrug; one of Q and T represents a group represented by the general formula: (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom; and with the proviso that P does not represent a hydrogen atom when R represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, which exert an inhibitory activity in human SGLT2 and have an improved oral absorption, and therefore are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutically acceptable salts thereof, and pharmaceutical uses thereof.
摘要翻译： 本发明提供由以下通式表示的吡喃葡萄糖氧吡唑衍生物：其中R表示氢原子，低级烷基或形成前药的基团; Q和T之一表示由通式表示的基团：（其中P表示氢原子或形成前药的基团），而另一个表示低级烷基或卤代（低级烷基）基团; R2表示氢原子，低级烷基，低级烷氧基，低级烷硫基，卤代（低级烷基）或卤素原子; 并且条件是当R表示氢原子或低级烷基时，P不表示氢原子，或其药学上可接受的盐，其在人SGLT2中具有抑制活性并具有改善的口服吸收，因此可用作 用于预防或治疗与高血糖相关的疾病如糖尿病，糖尿病并发症或肥胖症的药剂及其药学上可接受的盐及其药学用途。
-
公开(公告)号：US20060025352A1
公开(公告)日：2006-02-02
申请号：US11247216
申请日：2005-10-12
申请人： Hideki Fujikura , Nobuhiko Fushimi , Toshihiro Nishimura , Takeshi Nakabayashi , Masayuki Isaji
发明人： Hideki Fujikura , Nobuhiko Fushimi , Toshihiro Nishimura , Takeshi Nakabayashi , Masayuki Isaji
IPC分类号： A61K31/7052 , C07H17/02
CPC分类号： A61K45/06 , A61K31/7056 , C07H17/02 , A61K2300/00
摘要： The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R represents a hydrogen atom, a lower alkyl group or a group forming a prodrug;.one of Q and T represents a group represented by the general formula: (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom; and with the proviso that P does not represent a hydrogen atom when R represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, which exert an inhibitory activity in human SGLT2 and have an improved oral absorption, and therefore are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutically acceptable salts thereof, and pharmaceutical uses thereof.
摘要翻译： 本发明提供由以下通式表示的吡喃葡萄糖氧吡唑衍生物：其中R表示氢原子，低级烷基或形成前药的基团; Q和T表示由以下通式表示的基团：（其中P表示 氢原子或形成前药的基团），而另一个表示低级烷基或卤代（低级烷基）基团; R 2表示氢原子，低级烷基，低级烷氧基，低级烷硫基，卤代（低级烷基）或卤素原子; 并且条件是当R表示氢原子或低级烷基时，P不表示氢原子，或其药学上可接受的盐，其在人SGLT2中具有抑制活性并具有改善的口服吸收，因此可用作 用于预防或治疗与高血糖相关的疾病如糖尿病，糖尿病并发症或肥胖症的药剂及其药学上可接受的盐及其药学用途。
-
公开(公告)号：US07541341B2
公开(公告)日：2009-06-02
申请号：US10467823
申请日：2002-02-13
申请人： Nobuhiko Fushimi , Kazuya Tatani , Hideki Fujikura , Toshihiro Nishimura , Minoru Fujioka , Takeshi Nakabayashi , Masayuki Isaji
发明人： Nobuhiko Fushimi , Kazuya Tatani , Hideki Fujikura , Toshihiro Nishimura , Minoru Fujioka , Takeshi Nakabayashi , Masayuki Isaji
CPC分类号： C07H15/203
摘要： The present invention provides glucopyranosyloxybenzylbenzene derivatives represented by the general formula: wherein P represents a hydrogen atom or a group forming a prodrug; R1 represents a hydrogen atom, an optionally substituted amino group, a carbamoyl group, an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, etc.; R2 represents a hydrogen atom or a lower alkyl group; and R3 represents an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted lower alkylthio group, etc., which have an improved oral absorption, and exert an inhibitory activity in human SGLT2, and therefore are useful as drugs for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, or pharmaceutically acceptable salts thereof, and pharmaceutical uses thereof.
摘要翻译： 本发明提供由以下通式表示的吡喃葡萄糖氧基苄基苯衍生物：其中P表示氢原子或形成前药的基团; R1表示氢原子，任选取代的氨基，氨基甲酰基，任选取代的低级烷基，任选取代的低级烷氧基等; R2表示氢原子或低级烷基; R3代表任意取代的低级烷基，任意取代的低级烷氧基，任意取代的低级烷硫基等，它们具有改善的口服吸收，并且在人SGLT2中具有抑制活性，因此可用作 预防或治疗与糖尿病，糖尿病并发症或肥胖症等高血糖相关的疾病或其药学上可接受的盐及其药学用途。
-
公开(公告)号：US07429568B2
公开(公告)日：2008-09-30
申请号：US11247332
申请日：2005-10-12
申请人： Hideki Fujikura , Nobuhiko Fushimi , Toshihiro Nishimura , Takeshi Nakabayashi , Masayuki Isaji
发明人： Hideki Fujikura , Nobuhiko Fushimi , Toshihiro Nishimura , Takeshi Nakabayashi , Masayuki Isaji
CPC分类号： A61K45/06 , A61K31/7056 , C07H17/02 , A61K2300/00
摘要： The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R represents a hydrogen atom, a lower alkyl group or a group forming a prodrug; one of Q and T represents a group represented by the general formula: (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom; and with the proviso that P does not represent a hydrogen atom when R represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, which exert an inhibitory activity in human SGLT2 and have an improved oral absorption, and therefore are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutically acceptable salts thereof, and pharmaceutical uses thereof.
摘要翻译： 本发明提供由以下通式表示的吡喃葡萄糖氧吡唑衍生物：其中R表示氢原子，低级烷基或形成前药的基团; Q和T之一表示由通式表示的基团：（其中P表示氢原子或形成前药的基团），而另一个表示低级烷基或卤代（低级烷基）基团; R 2表示氢原子，低级烷基，低级烷氧基，低级烷硫基，卤代（低级烷基）或卤素原子; 并且条件是当R表示氢原子或低级烷基时，P不表示氢原子，或其药学上可接受的盐，其在人SGLT2中具有抑制活性并具有改善的口服吸收，因此可用作 用于预防或治疗与高血糖相关的疾病如糖尿病，糖尿病并发症或肥胖症的药剂及其药学上可接受的盐及其药学用途。
-
公开(公告)号：US07084123B2
公开(公告)日：2006-08-01
申请号：US10451926
申请日：2001-12-25
申请人： Hideki Fujikura , Nobuhiko Fushimi , Toshihiro Nishimura , Takeshi Nakabayashi , Masayuki Isaji
发明人： Hideki Fujikura , Nobuhiko Fushimi , Toshihiro Nishimura , Takeshi Nakabayashi , Masayuki Isaji
CPC分类号： A61K45/06 , A61K31/7056 , C07H17/02 , A61K2300/00
摘要： The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R represents a hydrogen atom, a lower alkyl group or a group forming a prodrug: one of Q and T represents a group represented by the general formula: (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom; and with the proviso that P does not represent a hydrogen atom when R represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, which exert an inhibitory activity in human SGLT2 and have an improved oral absorption, and therefore are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutically acceptable salts thereof, and pharmaceutical uses thereof.
摘要翻译： 本发明提供由以下通式表示的吡喃葡萄糖氧吡唑衍生物：其中R表示氢原子，低级烷基或形成前药的基团：Q和T之一表示由通式表示的基团：（其中P表示氢 原子或形成前药的基团），而另一个表示低级烷基或卤代（低级烷基）基团; R 2表示氢原子，低级烷基，低级烷氧基，低级烷硫基，卤代（低级烷基）或卤素原子; 并且条件是当R表示氢原子或低级烷基时，P不表示氢原子，或其药学上可接受的盐，其在人SGLT2中具有抑制活性并具有改善的口服吸收，因此可用作 用于预防或治疗与高血糖相关的疾病如糖尿病，糖尿病并发症或肥胖症的药剂及其药学上可接受的盐及其药学用途。
-
公开(公告)号：US20060094667A1
公开(公告)日：2006-05-04
申请号：US11247332
申请日：2005-10-12
申请人： Hideki Fujikura , Nobuhiko Fushimi , Toshihiro Nishimura , Takeshi Nakabayashi , Masayuki Isaji
发明人： Hideki Fujikura , Nobuhiko Fushimi , Toshihiro Nishimura , Takeshi Nakabayashi , Masayuki Isaji
IPC分类号： A61K31/7052 , C07H17/02
CPC分类号： A61K45/06 , A61K31/7056 , C07H17/02 , A61K2300/00
摘要： The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R represents a hydrogen atom, a lower alkyl group or a group forming a prodrug;.one of Q and T represents a group represented by the general formula: (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo (lower alkyl) group or a halogen atom; and with the proviso that P does not represent a hydrogen atom when R represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, which exert an inhibitory activity in human SGLT2 and have an improved oral absorption, and therefore are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutically acceptable salts thereof, and pharmaceutical uses thereof.
摘要翻译： 本发明提供由以下通式表示的吡喃葡萄糖氧吡唑衍生物：其中R表示氢原子，低级烷基或形成前药的基团; Q和T表示由以下通式表示的基团：（其中P表示 氢原子或形成前药的基团），而另一个表示低级烷基或卤代（低级烷基）基团; R 2表示氢原子，低级烷基，低级烷氧基，低级烷硫基，卤代（低级烷基）或卤素原子; 并且条件是当R表示氢原子或低级烷基时，P不表示氢原子，或其药学上可接受的盐，其在人SGLT2中具有抑制活性并具有改善的口服吸收，因此可用作 用于预防或治疗与高血糖相关的疾病如糖尿病，糖尿病并发症或肥胖症的药剂及其药学上可接受的盐及其药学用途。
-
-
-
-
-
-
-
-
-
搜索结果
67 条记录 (耗时 0.035 秒)
